RxDoctor Payments Data

Michael Macquarrie, MD

General Practice · Murfreesboro, TNNPI 1790766590

Payments from drug & device makers

$673in general payments, 2019–2025

Across 21 payments — averaging $32.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$249
  • Lilly USA, LLC$167
  • Merck$100
  • AbbVie$97
  • Pfizer$47
  • Boston Scientific$13

What the payments were for

  • Food & beverage$673100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca7$249
Lilly USA, LLC4$167
Merck5$100
AbbVie1$97
Pfizer3$47
Boston Scientific1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$673 in reported general payments places this provider in the 70th percentile of 1,632 general practice providers in Tennessee.

See all general practice providers in Tennessee

Medicare billing

Part B allowed, 2024
$62,524
Medicare patients
130
Services billed
2,394

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide59$55,961
EliquisApixaban52$50,353
JardianceEmpagliflozin32$33,151
OxycontinOxycodone Hcl13$20,264
Synjardy XrEmpagliflozin/Metformin Hcl12$13,758
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$13,003
LinzessLinaclotide15$11,976
XareltoRivaroxaban20$11,956
Trijardy XrEmpaglifloz/Linaglip/Metformin22$9,765
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$9,209
Janumet XrSitagliptin Phos/Metformin Hcl12$6,919
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$6,878
Breo ElliptaFluticasone/Vilanterol13$5,880
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen159$4,084
Atorvastatin Calcium336$3,809

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$47$50,35352 claims
AbbVieLinzess$97$11,97615 claims
AstraZenecaBreztri Aerosphere$249$9,20915 claims
MerckJanumet Xr$100$6,91912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,632 general practice providers in Tennessee.

Other general practice in Murfreesboro

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →